Univercells

OverviewSuggest Edit

Univercells is a One-stop-shop for high-density low-cost biomanufacturing "end-to-end"​ solutions, with innovative engineering able to decrease the needs for investments of over 75% and the cost of goods of up to 90%.

Univercells'​ technologies, aimed at low cost manufacturing of antibodies/proteins/vaccines, is based on single-use technologies, and chaining of three manufacturing steps into simulated continuous mode : cell culture under perfusion, clarification and capture.

Univercells positions itself as a global partner for developing biomanufacturing/biosimilar solution, going from the process design, to the selection of the best technologies (USP, DSP, filing technologies, etc), to the design of the clinical plan, the process development, the technology transfer, the facility construction or the training of the staff.

TypePrivate
Founded2013
HQCharleroi, BE
Websiteunivercells.com

Recent NewsAll News

Latest Updates

Employees (est.) (Jan 2021)133(+8%)
Cybersecurity ratingBMore

Key People/Management at Univercells

Hugues Bultot

Hugues Bultot

Chief Executive Officer, Co-Founder
Jose Castillo

Jose Castillo

Chief Technical Officer & Co-Founder
Mathias Garny

Mathias Garny

Chief Commercial Officer
Vincent Vanderborght

Vincent Vanderborght

CFO
Christian Borgniet

Christian Borgniet

COO
Cécile Jacoby

Cécile Jacoby

Chief Project Officer
Show more

Univercells Office Locations

Univercells has offices in Charleroi, Nivelles and Woluwe-Saint-Pierre
Charleroi, BE (HQ)
Rue Auguste Piccard 48
Nivelles, BE
Rue de la Maîtrise
Woluwe-Saint-Pierre, BE
Avenue de Tervueren 270
Show all (3)

Univercells Financials and Metrics

Summary Metrics

Founding Date

2013

Univercells total Funding

$37.7 m

Univercells latest funding size

$18.80 m

Time since last funding

3 years ago

Univercells investors

Univercells's latest funding round in July 2018 was reported to be $18.8 m. In total, Univercells has raised $37.7 m
Show all financial metrics

Univercells Cybersecurity Score

Cybersecurity ratingPremium dataset

B

88/100

SecurityScorecard logo

Univercells Online and Social Media Presence

Embed Graph

Univercells News and Updates

Univercells nets $3.56 mln Series A

Univercells, a Belgian provider of biomanufacturing solutions, has raised $3.56 million in Series A funding. The investors included Takeda Ventures Inc.

Univercells Blogs

Univercells Holding raises €70 million in Series C Financing

Univercells Holding recently raises €70 million with two rounds of capital increase with new investors. The capital infusion will support the development of GMP facilities and the capacity to foster distributed manufacturing and supply of biologics. The post Univercells Holding raises €70 million i…

Univercells Technologies introduces the NevoLine™ Upstream Platform

The new generation NevoLine platform redefines upstream processing by integrating virus production, concentration and clarification for streamlined, high-performance virus manufacturing The post Univercells Technologies introduces the NevoLine™ Upstream Platform appeared first on Univercells.

Univercells Technologies is building capacity for gene therapy production

The post Univercells Technologies is building capacity for gene therapy production appeared first on Univercells.

Exyte & Univercells Technologies combine forces for rapid deployment of vaccine production plants in the wake of the COVID-19 pandemic

Exyte, world-renowned for the design and construction of high-tech facilities, and Univercells Technologies, a provider of novel biomanufacturing technologies for economic and scalable viral production, are announcing a global partnership for optimized construction of modular standardized and flexib…

Launch of Univercells Technologies for intensified, automated technologies

The new brand aims at deploying Univercells’ technologies by accelerating the commercialization of the scale-X™ bioreactor portfolio and the NevoLine™ platform. The post Launch of Univercells Technologies for intensified, automated technologies appeared first on Univercells.

ReiThera, Leukocare and Univercells announce fast-track development of a COVID-19 vaccine

Italian ReiThera Srl., Rome, German LEUKOCARE AG, Munich, and Belgian Univercells S.A., Brussels, today announced a strategic collaboration for the development and large-scale manufacturing of a novel adenoviral vector-based vaccine against COVID-19. The post ReiThera, Leukocare and Univercells ann…
Show more

Univercells Frequently Asked Questions

  • When was Univercells founded?

    Univercells was founded in 2013.

  • Who are Univercells key executives?

    Univercells's key executives are Hugues Bultot, Jose Castillo and Mathias Garny.

  • How many employees does Univercells have?

    Univercells has 133 employees.

  • Who are Univercells competitors?

    Competitors of Univercells include SmartZyme, Servier and NovaBay Pharmaceuticals.

  • Where is Univercells headquarters?

    Univercells headquarters is located at Rue Auguste Piccard 48, Charleroi.

  • Where are Univercells offices?

    Univercells has offices in Charleroi, Nivelles and Woluwe-Saint-Pierre.

  • How many offices does Univercells have?

    Univercells has 3 offices.